Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

Completed · Not applicable

Conditions studied: AKI, Contrast-induced Nephropathy

In brief

This study will collect high-quality randomized controlled data across the U.S. from practicing cardiologists performing invasive/interventional procedures and determine how they currently manage patients at risk for CIN and how the results of Hikari's L-FABP test change clinical decision making.

Key facts

Study ID

NCT04266834

Run by

Qure Healthcare, LLC

People needed

157

Starts

2019-12-01

Expected to finish

2020-06-30

Last updated by the study team

2020-09-16

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Board-certified in cardiology for at least two years
• Averaging at least 20 hours per week of clinical and patient care duties over the last six months
• Averaging at least one day per month performing invasive or interventional cardiology procedures over the last six months
• English speaking
• Access to the internet
• Informed, signed and voluntarily consented to be in the study

You may not qualify if…

• Non-English speaking
• Unable to access the internet
• Do not voluntarily consent to be in the study

Where it is running

• QURE Healthcare — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.